Is SPPI stock a buy?
The consensus among 1 Wall Street analyst covering (NASDAQ: SPPI) stock is to Strong Buy SPPI stock.
What does Spectrum Pharma do?
Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted drug products, with a primary focus in hematology and oncology. Spectrum has a strong track record for in-licensing and acquiring differentiated drugs, and for clinical development.
What drugs does Spectrum Pharmaceuticals make?
Approved drugs Folotyn (pralatrexate) is an antifolate drug marketed for relapsed or refractory peripheral T-cell lymphoma. Khapzory (levoleucovorin) (Disodium Levoleucovorin), for injection, a folate analog for three indications: Rescue after high-dose methotrexate therapy in patients with osteosarcoma.
Will Sppi go up?
Spectrum Pharmaceuticals Inc (NASDAQ:SPPI) The 5 analysts offering 12-month price forecasts for Spectrum Pharmaceuticals Inc have a median target of 4.00, with a high estimate of 10.00 and a low estimate of 3.00. The median estimate represents a +421.72% increase from the last price of 0.77.
Is Spectrum Pharmaceuticals stock good?
Spectrum Pharmaceuticals has received a consensus rating of Buy. The company’s average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Will Sppi get FDA approval?
–(BUSINESS WIRE)– Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today that the U.S. Food and Drug Administration (FDA) has granted Accelerated Approval of Beleodaq™ for the …
What does Rolontis do?
About ROLONTIS ROLONTIS is a novel, long-acting granulocyte colony-stimulating factor (G-CSF) seeking an indication for the treatment of neutropenia in patients receiving myelosuppressive anti-cancer drugs.
Will Spectrum Pharmaceuticals go up?
The 5 analysts offering 12-month price forecasts for Spectrum Pharmaceuticals Inc have a median target of 4.00, with a high estimate of 10.00 and a low estimate of 3.00. The median estimate represents a +389.90% increase from the last price of 0.82.
Why is Sppi going down?
The big decline came after the company announced that the U.S. Food and Drug Administration turned down approval of Rolontis in treating neutropenia in patients receiving cancer drugs that decrease bone marrow activity.
How do I invest in spectrum?
How to buy shares in Spectrum Brands
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details.
- Research the stock.
- Purchase now or later.
- Check in on your investment.
What is a spectrum fund?
The Spectrum Fund pursues its objective by taking long and short positions in the global securities markets. The Fund primarily invests its long positions in common stocks and investment companies which include domestic and foreign mutual funds and exchange traded funds.
What company owns TikTok?
ByteDance
Currently, Chinese company ByteDance owns TikTok. Zhang Yiming is the owner and founder.
Is TikTok a CEO?
Shou Zi Chew (born 1 January 1983) is a Singaporean businessman. He is the CEO of social networking company TikTok and the CFO of its parent company, ByteDance.
How do chemotherapeutic agents work?
Chemotherapeutic agents are typically classified based on factors like chemical structure and how they work to treat cancer. The cell cycle is the process that cells in the body use to grow and divide. Chemotherapeutic agents work by targeting phases in the cell cycle.
What are some examples of chemotherapeutic agents?
It’s also possible that chemotherapeutic agents may be given along with other types of cancer treatments. Some examples include radiation therapy and targeted therapy. How are chemotherapeutic agents chosen?
Is broad-spectrum therapy the best option for immortalized cells?
But in any event, having a non-toxic, broad-spectrum therapeutic option that can be initiated rapidly after diagnosis, and used in concert with a narrowly targeted therapy would still be the best way to reach small and/or unidentified subpopulations of other types of mutant immortalized cells and reduce the chances of a relapse.
What is broad-spectrum combination therapy?
Conceptually speaking, a broad-spectrum combination therapy that can simultaneously target many of the key anti-cancer receptors, pathways and mechanisms with little-to-no toxicity makes a lot of sense.